| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 15, 2010Late Breaking Clinical Trial at 59th Annual Scientific Session of the American College of Cardiology (ACC) also Showed Shortened Cardiovascular Hospital Stays
MINNEAPOLIS & ATLANTA, Mar 15, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced results from the CONNECT trial showing the median time to clinical decision was significantly...
-
Mar 14, 2010Independent Analysis of Large and Comprehensive ENDEAVOR Program Shows Remarkably Durable Safety and Efficacy at Five Years of Follow Up in Coronary Artery Disease Patients
MINNEAPOLIS & ALTANTA, Mar 14, 2010 (BUSINESS WIRE) -- The consistency and quality of the long-term clinical results for the Endeavor(R) drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT),...
-
Mar 12, 2010Post-Market Evaluation of Breakthrough Medical Device Begins Enrolling Patients; First Implants Occur in Germany
MINNEAPOLIS, Mar 12, 2010 (BUSINESS WIRE) -- Moving to expand the evidence base for the future of structural heart disease therapy,Medtronic, Inc. (NYSE: MDT), today announced the start of the...
-
Feb 23, 2010Non-GAAP diluted EPS of $0.77 grew 8%; GAAP diluted EPS of $0.75 grew 21%International revenue of $1.615 billion grew 11% on a constant currency basis; 22% as reportedFree cash flow exceeds $1.3 billion; GAAP cash flow from operations of $1.488 billionWorldwide ICD revenue growth of 5% on a constant currency basis; 9% as reportedWorldwide CardioVascular revenue growth of 21% on a constant currency basis; 28% as reported
MINNEAPOLIS, Feb 23, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today reported financial results for the third quarter of fiscal year 2010, which ended January 29, 2010. The company...
-
Feb 23, 2010
MINNEAPOLIS, Feb 24, 2010 (BUSINESS WIRE) -- Medtronic, Inc., (NYSE: MDT), today announced William A. Hawkins, chairman and CEO, has been elected a Fellow of the American Institute of Medical and...
